AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9524980 — intervention group
Group type: EXPERIMENTAL
Intervention: +/- pindolol (30 mg, oral dose)
Number of subjects: 40
Study 9524980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acid pyrophosphate (SAPP) 1.1 g/200 ml
Number of subjects: 8
Study 7640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 2.264 g/200 ml
Number of subjects: 8
Study 7640144 — intervention group
Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 8
Study 7640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 4.08 g/200 ml
Number of subjects: 8
Study 2707251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) at doses ranging from 1 to 4 g/day for 13-15 months
Number of subjects: 19
Study 2707251 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 19
Study 73849 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa with carbidopa 66 mg/day
Number of subjects: 19
Study 73849 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa with benserazide 151 mg/day
Number of subjects: 19
Study 73849 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference between treatments
Number of subjects: 19
Study 73849 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of treatments
Number of subjects: 19
Study 30684563 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil
Number of subjects: 0
Study 30684563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28844591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125mg on day 1 and 80mg on days 2 & 3
Number of subjects: 15
Study 28844591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 888
Study 22307212 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized phase II trials assessing systemic cancer therapies
Number of subjects: 107
Study 22307212 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of formal statistical testing (P values or CIs)
Number of subjects: 107
Study 22307212 — intervention group
Group type: COMPARATOR
Intervention: Control group presence
Number of subjects: 107
Study 22289537 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM‐AC (gemcitabine adsorbed onto activated carbon particles)
Number of subjects: 8
Study 22289537 — intervention group
Group type: COMPARATOR
Intervention: GEM‐Sol (gemcitabine solution)
Number of subjects: 8
Study 19581197 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK intervention
Number of subjects: 40
Study 19581197 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 40
Study 16454930 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 78
Study 16454930 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 78
Study 15003077 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR (12.5-37.5 mg/day)
Number of subjects: 370
Study 15003077 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 370
Study 15003077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 11699398 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outpatient supportive care following induction chemotherapy with cytosine arabinoside and an anthracycline.
Number of subjects: 19
Study 11699398 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care (control group).
Number of subjects: 19
Study 9608962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg.kg‐1
Number of subjects: 80
Study 9608962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg.kg‐1 plus intranasal atropine 0.02 mg.kg‐1
Number of subjects: 80
Study 9608962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.25 mg.kg‐1 plus intramuscular atropine 0.02 mg.kg‐1
Number of subjects: 80
Study 9608962 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline drops
Number of subjects: 80
Study 8022946 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% THC
Number of subjects: 10
Study 8022946 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.55% THC
Number of subjects: 10
Study 8022946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2685215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for more than two weeks
Number of subjects: 193
Study 2685215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 193
Study 2685215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL)
Number of subjects: 193
Study 4758423 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 200 mg by mouth at the beginning and end of each dialysis
Number of subjects: 0
Study 4758423 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 0
Study 31274239 — intervention group
Group type: EXPERIMENTAL
Intervention: EIS + IACIT
Number of subjects: 0
Study 31274239 — intervention group
Group type: COMPARATOR
Intervention: EIS only
Number of subjects: 0
Study 30964698 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy before surgery (RS)
Number of subjects: 0
Study 30964698 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by radiotherapy (SR)
Number of subjects: 0
Study 28619294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE) 1000mg standardized, given three times daily with meals for 3 months
Number of subjects: 24
Study 28619294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE)
Number of subjects: 24
Study 28619294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26051158 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG marker system
Number of subjects: 55
Study 23442287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced whey protein with low-volume resistance training (BWPLV)
Number of subjects: 106
Study 23442287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced whey protein with moderate-volume resistance training (BWPMV)
Number of subjects: 106
Study 23442287 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard whey protein with moderate-volume resistance training (SWPMV)
Number of subjects: 106
Study 23442287 — intervention group
Group type: COMPARATOR
Intervention: Placebo with moderate-volume resistance training (PLA)
Number of subjects: 106
Study 23442287 — intervention group
Group type: COMPARATOR
Intervention: Control with moderate-volume resistance training (CON)
Number of subjects: 106
Study 20934270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with lymph nodes examined
Number of subjects: 445
Study 18062846 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 276
Study 18062846 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 276
Study 16565634 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite care in the VA SUD clinic
Number of subjects: 720
Study 16565634 — intervention group
Group type: COMPARATOR
Intervention: Referral care in the VA general internal medicine clinic
Number of subjects: 720
Study 12503834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 24
Study 12503834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10088561 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 57
Study 10088561 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681311 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study 1822833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg chronic administration
Number of subjects: 18
Study 1822833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg acute administration
Number of subjects: 18
Study 1822833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1822833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (5 mg or 10 mg)
Number of subjects: 18
Study 1822833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 18
Study 1822833 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 18
Study 6798765 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation I (SH D 356 A) containing 75 micrograms delta 15-d-norgestrel (Gestoden) + 30 micrograms ethinyloestradiol
Number of subjects: 20
Study 6798765 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation II (SH D 356 B) containing 75 micrograms d-norgestrel + 30 micrograms ethinyloestradiol
Number of subjects: 20
Study 6494382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP)
Number of subjects: 0
Study 6494382 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 6494382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 31436181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical olopatadine (0.1%)
Number of subjects: 45
Study 31436181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bepotastine (1.5%)
Number of subjects: 45
Study 31436181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alcaftadine (0.25%)
Number of subjects: 45
Study 31436181 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 30342467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus low dose of dexmedetomidine (0.02 μg/kg/h each, Group D1)
Number of subjects: 90
Study 30342467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus high dose of dexmedetomidine (0.04 μg/kg/h, Group D2)
Number of subjects: 90
Study 30342467 — intervention group
Group type: COMPARATOR
Intervention: Control (sufentanil 0.02 μg/kg/h, Group C)
Number of subjects: 90
Study 27329516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sleep chocolate milk (CM)
Number of subjects: 12
Study 27329516 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive placebo (PL)
Number of subjects: 12
Study 23856151 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict education on clinical practice guidelines by a physical therapist and an occupational therapist
Number of subjects: 37
Study 23856151 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy services
Number of subjects: 37
Study 22820898 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-mg daily
Number of subjects: 240
Study 22820898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 20194854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (arm B)
Number of subjects: 400
Study 20194854 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (arm A)
Number of subjects: 400
Study 18831882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (ethyl-EPA)
Number of subjects: 34
Study 18831882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15699018 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure treatment for 6 months
Number of subjects: 27
Study 15699018 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 27
Study 11815429 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency pulse applied at the site with mechanical translation
Number of subjects: 9
Study 11815429 — intervention group
Group type: EXPERIMENTAL
Intervention: Single radiofrequency pulse applied at the site with diastolic potential
Number of subjects: 9
Study 11815429 — intervention group
Group type: EXPERIMENTAL
Intervention: Three radiofrequency pulses delivered to the site with the earliest retroPP
Number of subjects: 9
Study 11815429 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 9
Study 10075297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 53
Study 10075297 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Control)
Number of subjects: 53
Study 7551301 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform
Number of subjects: 30
Study 7551301 — intervention group
Group type: COMPARATOR
Intervention: 125-microF biphasic waveform
Number of subjects: 30
Study 7551301 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform with endocardial lead system
Number of subjects: 30
Study 7551301 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform with endocardial-subcutaneous array lead system
Number of subjects: 30
Study 2123355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mackerel supplement (135 g per day for 6 weeks)
Number of subjects: 40
Study 2123355 — intervention group
Group type: COMPARATOR
Intervention: Meat (control) paste (135 g per day for 6 weeks)
Number of subjects: 40
Study 7362089 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline tablet (2.5, 3.75, or 5.0 mg depending on weight)
Number of subjects: 16
Study 7362089 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline oral solution (2.5, 3.75, or 5.0 mg depending on weight)
Number of subjects: 16
Study 7362089 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 16
Study 30683249 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative evidence based bundle/standard education
Number of subjects: 50
Study 30683249 — intervention group
Group type: COMPARATOR
Intervention: Standard education packet
Number of subjects: 50
Study 27865446 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan 100 mg
Number of subjects: 150
Study 27865446 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan 200 mg
Number of subjects: 150
Study 26471076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based breakfasts and fruit products (salad and juice) consumed within breakfast or as a midmorning snack
Number of subjects: 9
Study 26471076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit salad consumed as a midmorning snack
Number of subjects: 9
Study 26471076 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of breakfast and whole fruit as midmorning snack
Number of subjects: 9
Study 23433054 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol extract of Sanyak
Number of subjects: 0
Study 23433054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanyak pharmacopuncture
Number of subjects: 0
Study 21831003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-talk focusing on group's capabilities
Number of subjects: 80
Study 21831003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-talk focusing on personal capabilities
Number of subjects: 80
Study 21831003 — intervention group
Group type: COMPARATOR
Intervention: Neutral statements (control condition)
Number of subjects: 80
Study 19507642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis using direct current (3 mA, 10 min) (n: 10, 28 TrPs)
Number of subjects: 20
Study 19507642 — intervention group
Group type: COMPARATOR
Intervention: Direct current only (n: 10, 30 TrPs)
Number of subjects: 20
Study 17642435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (ACE inhibitors, sartans, hypolipidemic drugs, drugs influencing proteinkinase C and vascular endothelial growth factor)
Number of subjects: 0
Study 17642435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Number of subjects: 0
Study 15226779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose neoadjuvant chemotherapy of epirubicin and cyclophosphamide
Number of subjects: 44
Study 15226779 — intervention group
Group type: EXPERIMENTAL
Intervention: ETAR-positive patients
Number of subjects: 44
Study 15226779 — intervention group
Group type: COMPARATOR
Intervention: ETAR-negative patients
Number of subjects: 44
Study 15226779 — intervention group
Group type: EXPERIMENTAL
Intervention: ETAR as a predictive marker
Number of subjects: 44
Study 12459619 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (EC40) applied every 6 months
Number of subjects: 238
Study 12459619 — intervention group
Group type: COMPARATOR
Intervention: Neutral gel (control group)
Number of subjects: 238
Study 9914578 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter insertion
Number of subjects: 149
Study 9914578 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 149
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA (Carcinoembryonic Antigen)
Number of subjects: 1023
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15.3
Number of subjects: 1023
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEA and CA 15.3
Number of subjects: 1023
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA (in ER+ patients)
Number of subjects: 1023
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15.3 (in PgR+ patients)
Number of subjects: 1023
Study 7579505 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA and CA 15.3
Number of subjects: 1023
Study 1962900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin), started in the evening before surgery and then every evening
Number of subjects: 1002
Study 1962900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin)
Number of subjects: 1002
Study 1962900 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 1002
Study 1962900 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin) and Conventional low-dose heparin
Number of subjects: 1002
Study 6764318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate eye drops
Number of subjects: 374
Study 6764318 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone phosphate eye drops
Number of subjects: 374
Study 6764318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate with neomycin
Number of subjects: 374
Study 6764318 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone with neomycin
Number of subjects: 374
Study 6764318 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone eye drops
Number of subjects: 374
Study 6764318 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone eye drops
Number of subjects: 374
Study 31937699 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care (KMC)
Number of subjects: 8402
Study 31937699 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 8402
Study 29391018 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weekly home visits from nursing students
Number of subjects: 98
Study 29391018 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 98
Study 26804639 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP) 75 µg, 300 µg, 1200 µg (single-dose study)
Number of subjects: 35
Study 26804639 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP) 60 µg, 120 µg, 180 µg, 240 µg BID (multiple-dose study)
Number of subjects: 35
Study 26804639 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP)
Number of subjects: 35
Study 24865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral coping skills training (CST)
Number of subjects: 264
Study 24865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 264
Study 24865870 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 264
Study 24865870 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 264
Study 22723176 — intervention group
Group type: EXPERIMENTAL
Intervention: verbascoside (1 mg/dL)
Number of subjects: 60
Study 22723176 — intervention group
Group type: EXPERIMENTAL
Intervention: verbascoside (2 mg/dL)
Number of subjects: 60
Study 22723176 — intervention group
Group type: COMPARATOR
Intervention: aspirin (100 μM)
Number of subjects: 60
Study 22723176 — intervention group
Group type: EXPERIMENTAL
Intervention: verbascoside (1 and 2 mg/dL)
Number of subjects: 60
Study 20105414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 84
Study 20105414 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessment-only)
Number of subjects: 84
Study 20105414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated students
Number of subjects: 84
Study 20105414 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary students
Number of subjects: 84
Study 17360767 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant weight loss (>10 kg reduction)
Number of subjects: 6894
Study 17360767 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant weight gain (>10 kg increase)
Number of subjects: 6894
Study 17360767 — intervention group
Group type: COMPARATOR
Intervention: Stable weight
Number of subjects: 6894
Study 15723979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 652
Study 15723979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 652
Study 15723979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 652